Same but different; the challenges faced by the GT community
POSTED
July 21, 2022
SHARE VIA
Glanzmann’s Thrombasthenia (GT) is a rare bleeding disorder, estimated to affect 1 in a million people. Compared to more “common” bleeding disorders such as hemophilia, GT receives a lot less attention when it comes to research and developments. Haemnet recently commenced the Glanzmann’s 360 Study which will explore the ways in which GT affects those who live with it and their families.
During our research we discovered the Glanzmann’s Research Foundation (GRF). In this episode of Haemcast, Kate Khair speaks with Taylor Anne Burtz and Peter Zdziarski, President and Vice President of the GRF respectively. Show notes:
Take part in the Glanzmann’s 360 Study
Join the Glanzmann’s Research Foundation support group – This group is for patients, family members, friends, and doctors of those affected by GT